Analyst says Parexel saw demand from small and mid-sized biopharmas decline in fiscal Q1

- Last updated on GMT

Related tags: Pharmacology

Analyst says Parexel saw demand from biopharmas decline in fiscal Q1
Analyst says Parexel saw demand from biopharmas decline in fiscal Q1
Parexel has seen small and mid-sized biopharma demand for development services decline in recent months according to an anaylst who attended the CROs presentation at the Jefferies Global Healthcare conference this week.

Parexel set up the biopharmaceuticals unit last summer​ in a bid to win more business from small and mid-sized biopharmaceutical firms and broaden its client base beyond its limited portfolio of Big Pharma strategic partners.

At the time COO Mark Goldberg told us the idea was to “apply best practices from our strategic partnerships and deliver them with the right scale, dedication and oversight to meet the needs of small and emerging [biopharma] companies.”

He suggested that although small and mid-sized developers biopharmaceutical developers control between 60 and 80% of the drug sector’s intellectual property, they need additional support.

The fate of a smaller company may pivot on the success of a particular program, and we must execute with an urgency that is commensurate with the responsibility for success that we carry in these relationships​.”

And the unit got off to a good start with double-digit growth in new business wins in fiscal Q4 2013​. At the time CEO Josef Von Rickenbach said that: “We are pleased with the results of our diversification efforts with respect to small and midsized clients, and expect to remain competitive in this area of the market​.”

However, in recent months this situation appears to have changed with the amount of new business Parexel has won from smaller biopharmaceutical firms slowing, according to analysts who attended the CROs presentation at the Jefferies Global Healthcare conference this week.

In an investor note summarising the presentation, analyst David Windley said: “[the BioPharm unit] fell well short of expectations in the September quarter​” adding that “two sizeable deals went to competitors​.”

We believe that at least four strategic partners have hit maturity levels that will see their revenues flatten going forward. New project awards will essentially replace projects that are completing.

“Thus, growth depends on layering on new client relationships or ramping business with small-cap biopharmas​.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars